Hypertension Diagnostics Inc. Announces to All Shareholders

TORONTO, ON / ACCESSWIRE / October 2, 2019 / There appears to be a control dispute for Hypertension Diagnostics, Inc. (OTC PINK:HDII) involving Mr. Liangjian Peng and another party. HDII’s attorney Stephen Mills is currently dealing with the dispute. We believe this matter will be solved very soon. Mr. Peng, CEO of HDII affirms that he is sole officer and only preferred shares holder of HDII. Mr. Peng will travel to China on October 4, 2019, he will visit ShanDong GerPang Healthcare Group to discuss further cooperation between HDII and ShanDong Gerpang Healthcare Group. Thank you for all shareholders support!

About ShanDong GerPang healthcare Group

The main focus of business for the Group includes bio-pharmaceutical R&D, development and sales of medical informatization software, introduction of technology-based medical interventions, as well as the production and sales of medical supplies, dietary supplements, medicines, and medical equipment supplies through a combination of in-house sales and a network of sales agents across China.

About Hypertension Diagnostics Inc.

Hypertension Diagnostics, Inc. is a public company currently trading on the OTC Markets (OTC: HDII). HDII was originally corporate in Minnesota.

*Safe Harbor Statement Information in this press release may contain ‘forward-looking statements.’ Statements describing objectives or goals or the Company’s future plans are also forward-looking statements and are subject to risks and uncertainties, including the financial performance of the Company and market valuations of its stock, which could cause actual results to differ materially from those anticipated. Forward-looking statements in this news release are made pursuant to the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to sales, acceptance of Hypertension Diagnostics Inc.’s products, increased levels of competition, changes, dependence on intellectual property rights and other risks detailed from time to time in Hypertension Diagnostics Inc. periodic reports filed with the regulatory authorities.


Jeff Peng
[email protected]

SOURCE: Hypertension Diagnostics Inc.

View source version on accesswire.com:

error: Content is protected !!